CSIMarket
 


United Cannabis Corp  (CNAB)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

CNAB's Capital Expenditures Growth by Quarter and Year

United Cannabis's Capital Expenditures results by quarter and year




CNAB Capital Expenditures (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - -0.08 0.43 -
III Quarter September 0.50 1.65 0.06 -
II Quarter June 0.51 0.55 0.20 -
I Quarter March 0.13 0.51 0.13 -
FY   1.14 2.63 0.82 -



CNAB Capital Expenditures third quarter 2019 Y/Y Growth Comment
United Cannabis Corp reported drop in Capital Expenditures in the third quarter by -69.55% to $ 0.50 millions, from the same quarter in 2018.
The fall in the third quarter United Cannabis Corp's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 310.81%.

Looking into third quarter results within Biotechnology & Drugs industry 76 other companies have achieved higher Capital Expenditures growth. While United Cannabis Corp' s Capital Expenditures meltdown of -69.55% ranks overall at the positon no. 2477 in the third quarter.




CNAB Capital Expenditures ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September -69.55 % 2650 % - -
II Quarter June -7.27 % 175 % - -
I Quarter March -74.51 % 292.31 % - -
FY   - 220.73 % - -

Financial Statements
United Cannabis's third quarter 2019 Capital Expenditures $ 0.50 millions CNAB's Income Statement
United Cannabis's third quarter 2018 Capital Expenditures $ 1.65 millions Quarterly CNAB's Income Statement
New: More CNAB's historic Capital Expenditures Growth >>


CNAB Capital Expenditures (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - - 616.67 % -
III Quarter September -1.5 % 200 % -70 % -
II Quarter June 292.31 % 7.84 % 53.85 % -
I Quarter March - 18.6 % - -
FY (Year on Year)   - 220.73 % - -




Capital Expenditures third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #77
Healthcare Sector #355
Overall #2477

Capital Expenditures Y/Y Growth Statistics
High Average Low
2779.19 % 310.81 % -100 %
(Sep 30 2018)   (Jun 30 2016)
Capital Expenditures third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #77
Healthcare Sector #355
Overall #2477
Capital Expenditures Y/Y Growth Statistics
High Average Low
2779.19 % 310.81 % -100 %
(Sep 30 2018)   (Jun 30 2016)

Capital Expenditures by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

United Cannabis's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
654.16 % 127.9 % -100 %
(Dec 31 2017)  


CNAB's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2019 United Cannabis Corp reported decrease in Capital Expenditures from the previous quarter by -1.5% to $ 0.50 millions, from $ 0.51 millions declared in the previous qaurter.

Even seasonal circumstance were not able to recover the III. Quarter for the United Cannabis Corp, Anika Mistry , Healthcare sector researcher allocated in Bengaluru said, she mentioned little skepticism towards United Cannabis's direction and mentioned that average sequential Capital Expenditures growth is at 127.9% for CNAB.

Within Biotechnology & Drugs industry 48 other companies have achieved higher Capital Expenditures quarter on quarter growth. While United Cannabis's Capital Expenditures growth quarter on quarter, overall rank is 1391.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #49
Healthcare Sector #229
Overall #1391
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #49
Healthcare Sector #229
Overall #1391
Capital Expenditures Q/Q Growth Statistics
High Average Low
654.16 % 127.9 % -100 %
(Dec 31 2017)  


CNAB's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2019 United Cannabis Corp reported decrease in Capital Expenditures sequentially by -1.5% to $ 0.50 millions, from $ 0.51 millions achived a quarter before.

Those cyclical factors that commonly fuel III. Quarter 2019 performance, were not able to recover the III. Quarter for the United Cannabis Corp, Anika Mistry , Healthcare sector researcher allocated in Bengaluru wrote, she identified further difficulties onward for the Biotechnology & Drugs's company and mentioned that average sequential Capital Expenditures growth is at 127.9% for the Biotechnology & Drugs's company.

Within Biotechnology & Drugs industry 48 other companies have achieved higher Capital Expenditures quarter on quarter growth. While United Cannabis's Capital Expenditures growth quarter on quarter, overall rank is 1391.


United Cannabis's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
Cumulative Capital Expenditures 12 Months Ending $ 1.06 $ 2.20 $ 2.24 $ 2.63 $ 3.14
Y / Y Capital Expenditures Growth (TTM) -66.41 % 41.58 % 86.7 % 221.1 % -
Year on Year Capital Expenditures Growth Overall Ranking # 2137 # 759 # 445 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) -52.01 % -1.92 % -14.64 % -16.39 % 102.26 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2408 # 1745 # 2290 # 458 # 102




Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2019 United Cannabis reported a sharp drop in Capital Expenditures by -66.41% year on year, to $1 millions, compare to the 41.58% growth at Jun 30 2019.

In the Healthcare sector 299 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 759 to 2137.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
102.26 %
13.35 %
-52.01 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 81
Healthcare Sector # 300
Overall # 2137

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
221.1 %
70.75 %
-66.41 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 372
S&P 500 # 2408
Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2019 United Cannabis reported a sharp drop in Capital Expenditures by -66.41% year on year, to $1 millions, compare to the 41.58% growth at Jun 30 2019.

In the Healthcare sector 299 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 759 to 2137.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
102.26 %
13.35 %
-52.01 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 81
Healthcare Sector # 300
Overall # 2137

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
221.1 %
70.75 %
-66.41 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 372
S&P 500 # 2408




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CNAB's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CNAB's Competitors
Capital Expenditures Growth for United Cannabis's Suppliers
Capital Expenditures Growth for CNAB's Customers

You may also want to know
CNAB's Annual Growth Rates CNAB's Profitability Ratios CNAB's Asset Turnover Ratio CNAB's Dividend Growth
CNAB's Roe CNAB's Valuation Ratios CNAB's Financial Strength Ratios CNAB's Dividend Payout Ratio
CNAB's Roa CNAB's Inventory Turnover Ratio CNAB's Growth Rates CNAB's Dividend Comparisons



Companies with similar Capital Expenditures sharp drop for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2019
Volitionrx Ltd -0.57 %$ -0.570 millions
Amgen Inc. -0.58 %$ -0.585 millions
Supernus Pharmaceuticals, inc. -1.49 %$ -1.493 millions
Eli Lilly And Company -2.37 %$ -2.372 millions
Nabriva Therapeutics Plc -2.44 %$ -2.439 millions
Cambrex Corp -3.12 %$ -3.117 millions
Retractable Technologies Inc -3.44 %$ -3.443 millions
Exact Sciences Corporation -3.65 %$ -3.646 millions
Surface Oncology, Inc. -5.26 %$ -5.263 millions
Laboratory Corp Of America Holdings -5.41 %$ -5.414 millions
Portola Pharmaceuticals, inc. -6.37 %$ -6.369 millions
Universal Health Services Inc -6.60 %$ -6.599 millions
Community Health Systems Inc -6.78 %$ -6.780 millions
Icu Medical Inc -7.31 %$ -7.305 millions
Edwards Lifesciences Corporation -7.31 %$ -7.308 millions
Zafgen, Inc. -7.89 %$ -7.895 millions
Milestone Scientific Inc. -8.21 %$ -8.207 millions
Myomo Inc -8.51 %$ -8.509 millions
Mri Interventions, Inc. -8.64 %$ -8.643 millions
Johnson & Johnson -9.04 %$ -9.035 millions
Novavax Inc -9.09 %$ -9.091 millions
Luna Innovations Inc -9.12 %$ -9.122 millions
Capital Senior Living Corp -9.69 %$ -9.690 millions
Cel Sci Corp -10.32 %$ -10.324 millions
Amedisys, Inc. -10.53 %$ -10.533 millions
Sintx Technologies, Inc. -10.64 %$ -10.638 millions
Ocular Therapeutix, Inc -11.42 %$ -11.416 millions
Select Medical Holdings Corp -11.98 %$ -11.982 millions
Sutro Biopharma, Inc. -12.12 %$ -12.121 millions
Intellia Therapeutics, Inc. -13.29 %$ -13.294 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SAVE's Profile

Stock Price

SAVE's Financials

Business Description

Fundamentals

Charts & Quotes

SAVE's News

Suppliers

SAVE's Competitors

Customers & Markets

Economic Indicators

SAVE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071